Journal articles: 'Antiretroviral Treatment'

1

Boelaert, Johan R., and Kirk Sperber. "Antiretroviral treatment." Lancet 352, no. 9135 (October 1998): 1224–25. http://dx.doi.org/10.1016/s0140-6736(05)60566-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lange, Joep M. A., David A. Cooper, and Sven A. Danner. "Antiretroviral treatment." AIDS 5, Supplement (January 1991): 181–88. http://dx.doi.org/10.1097/00002030-199101001-00026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Maeland, Arild. "Antiretroviral treatment initiation." Lancet Infectious Diseases 14, no. 12 (December 2014): 1175. http://dx.doi.org/10.1016/s1473-3099(14)70947-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Gupta, Samir K. "Antiretroviral treatment initiation." Lancet Infectious Diseases 14, no. 12 (December 2014): 1175–76. http://dx.doi.org/10.1016/s1473-3099(14)70951-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Harris, Marianne. "Raltegravir: Its use in the Treatment of HIV Infection." Clinical Medicine. Therapeutics 1 (January 2009): CMT.S32. http://dx.doi.org/10.4137/cmt.s32.

Full text

Abstract:

Raltegravir is the first integrase strand transfer inhibitor to be approved for the treatment of HIV infection. Administered orally in doses of 400 mg twice daily, it is well-tolerated and has minimal drug-drug interactions with coadministered antiretrovirals and other agents. In clinical trials including treatment-experienced and treatment-naïve HIV-infected adults, raltegravir in combination with other antiretroviral agents has demonstrated a rapid and potent virologic effect and a generally benign safety profile. Like other antiretrovirals, raltegravir should ideally be given with two additional agents to which the patient's virus is susceptible based on results of resistance testing. In this context, raltegravir offers a safe and effective option as a component of combination therapy in treatment-experienced patients who are infected with HIV-1 strains showing evidence of resistance to other antiretroviral agents. Pending the availability of longer-term efficacy and safety data, raltegravir cannot currently be recommended as part of first-line therapy for treatment-naïve patients.

APA, Harvard, Vancouver, ISO, and other styles

6

Montaner, Julio SG, Robert Hogg, Janet Raboud, Richard Harrigan, and Michael O'Shaughnessy. "Antiretroviral treatment in 1998." Lancet 352, no. 9144 (December 1998): 1919–22. http://dx.doi.org/10.1016/s0140-6736(98)07532-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Keiser, Olivia, Angèle Gayet-Ageron, Christoph Rudin, Martin WG Brinkhof, Erika Gremlich, Dorothea Wunder, Gero Drack, Bernard Hirschel, and Begoña Martinez de Tejada. "Antiretroviral treatment during pregnancy." AIDS 22, no. 17 (November 2008): 2323–30. http://dx.doi.org/10.1097/qad.0b013e3283189bf1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Arduino, R. "New antiretroviral treatment options." International Journal of Infectious Diseases 73 (August 2018): 37. http://dx.doi.org/10.1016/j.ijid.2018.04.3505.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Stek, Alice Marie. "Antiretroviral treatment in pregnancy." Current Opinion in HIV and AIDS 3, no. 2 (March 2008): 155–60. http://dx.doi.org/10.1097/coh.0b013e3282f50bfe.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Hammer, Scott M. "Antiretroviral Treatment as Prevention." New England Journal of Medicine 365, no. 6 (August 11, 2011): 561–62. http://dx.doi.org/10.1056/nejme1107487.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Geffen, Nathan, M. Robinson, F. Venter, and M. Low. "One size doesn’t fit all: Tailoring adult antiretroviral treatment." Southern African Journal of HIV Medicine 15, no. 3 (September 8, 2014): 77–78. http://dx.doi.org/10.4102/sajhivmed.v15i3.6.

Full text

Abstract:

Advances in antiretroviral treatment mean that patients in the public health system can be given more options in the management of their treatment. Although public health programmes tend to offer one-size-fits-all approaches, patients might benefit from a more flexible approach. In particular, we propose that people with HIV should be given more choice with regard to when to start treatment, and patients who experience efavirenz side-effects should be encouraged to switch to other medications, which will be facilitated by faster registration and lower prices of newer antiretrovirals.

APA, Harvard, Vancouver, ISO, and other styles

12

Schnittman, Steven M. "Treatment of HIV-1 Infection with Combination Therapy: Antiretroviral Agents and Biological Response Modifiers." Canadian Journal of Infectious Diseases 5, suppl a (1994): 42A—46A. http://dx.doi.org/10.1155/1994/134340.

Full text

Abstract:

While nucleoside antiretroviral agents are effective in delaying disease progression in human immunodeficiency virus (HIV - infected individuals. their activity is limited in magnitude and duration. Therefore, approaches to attacking HIV via combination therapies have recently been under investigation. In particular, since HIV infection dysregulates and destroys the immune system. it is logical to develop therapeutic approaches that would both restore the immune response and have direct antiviral activity. Preliminary evaluations of the combination of zidovudine wilh interferon alpha (IFN-α) have demonstrated enhanced antiviral. antitumour and immunomodulatory activity. Other promising approaches include antiretroviral therapy with interleukin (IL) -2, and IFN-α wilh IL-2. The clinical research pertaining to these combinations of antiretrovirals and biological response modifiers is reviewed.

APA, Harvard, Vancouver, ISO, and other styles

13

Yu, Zaikuan J., Eric P. Mosher, and Namandjé N. Bumpus. "Pharmacogenomics of Antiretroviral Drug Metabolism and Transport." Annual Review of Pharmacology and Toxicology 61, no. 1 (January 6, 2021): 565–85. http://dx.doi.org/10.1146/annurev-pharmtox-021320-111248.

Full text

Abstract:

Antiretroviral therapy has markedly reduced morbidity and mortality for persons living with human immunodeficiency virus (HIV). Individual tailoring of antiretroviral regimens has the potential to further improve the long-term management of HIV through the mitigation of treatment failure and drug-induced toxicities. While the mechanisms underlying anti-HIV drug adverse outcomes are multifactorial, the application of drug-specific pharmacogenomic knowledge is required in order to move toward the personalization of HIV therapy. Thus, detailed understanding of the metabolism and transport of antiretrovirals and the influence of genetics on these pathways is important. To this end, this review provides an up-to-date overview of the metabolism of anti-HIV therapeutics and the impact of genetic variation in drug metabolism and transport on the treatment of HIV. Future perspectives on and current challenges in pursuing personalized HIV treatment are also discussed.

APA, Harvard, Vancouver, ISO, and other styles

14

Marfatia, Yogesh, Ajay Sharma, Roshni Vora, Megha Modi, and Archana Sharma. "Adverse effects of antiretroviral treatment." Indian Journal of Dermatology, Venereology and Leprology 74, no. 3 (2008): 234. http://dx.doi.org/10.4103/0378-6323.41368.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Nolan, Seonaid, Evan Wood, and Julio S. G. Montaner. "Antiretroviral treatment initiation – Authors' reply." Lancet Infectious Diseases 14, no. 12 (December 2014): 1176–77. http://dx.doi.org/10.1016/s1473-3099(14)71005-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Ricci, E., F. Parazzini, and G. Pardi. "Caesarean section and antiretroviral treatment." Lancet 355, no. 9202 (February 2000): 496. http://dx.doi.org/10.1016/s0140-6736(00)82051-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Grierson, JG, SA Misson, and MK Pitts. "Correlates of antiretroviral treatment breaks." HIV Medicine 5, no. 1 (January 2004): 34–39. http://dx.doi.org/10.1111/j.1468-1293.2004.00183.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Emanuele, Pontali. "Antiretroviral Treatment in Correctional Facilities." HIV Clinical Trials 6, no. 1 (February 2005): 25–37. http://dx.doi.org/10.1310/gtqm-qrm1-fdw8-y2ft.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Kyriakides, Tassos C. "Timing of Antiretroviral Treatment Initiation." JAMA 285, no. 13 (April 4, 2001): 1702. http://dx.doi.org/10.1001/jama.285.13.1702.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Forstein, Marshall. "Psychosocial issues in antiretroviral treatment." New Directions for Mental Health Services 2000, no. 87 (2000): 17–24. http://dx.doi.org/10.1002/yd.23320008704.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Cahn, P. "Novel strategies for antiretroviral treatment." International Journal of Infectious Diseases 73 (August 2018): 37–38. http://dx.doi.org/10.1016/j.ijid.2018.04.3506.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Lawn, Stephen D., and Diana N. J. Lockwood. "Leprosy after starting antiretroviral treatment." BMJ 334, no. 7587 (February 1, 2007): 217–18. http://dx.doi.org/10.1136/bmj.39107.480359.80.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Bailey, A. C., and M. Fisher. "Current use of antiretroviral treatment." British Medical Bulletin 87, no. 1 (August 1, 2008): 175–92. http://dx.doi.org/10.1093/bmb/ldn032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Badowski, Melissa E., Sarah E. Pérez, Mark Biagi, and John A. Littler. "New Antiretroviral Treatment for HIV." Infectious Diseases and Therapy 5, no. 3 (August 18, 2016): 329–52. http://dx.doi.org/10.1007/s40121-016-0126-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Lopes, Carmen Andréa F., Marcelo A. Soares, Diego R. Falci, and Eduardo Sprinz. "The Evolving Genotypic Profile of HIV-1 Mutations Related to Antiretroviral Treatment in the North Region of Brazil." BioMed Research International 2015 (2015): 1–6. http://dx.doi.org/10.1155/2015/738528.

Full text

Abstract:

HIV related mutations can be associated with decreased susceptibility to antiretrovirals and treatment failures. There is scarce information about HIV mutations in persons failing HIV treatment in North of Brazil. Our aim was to evaluate evolution of HIV subtypes and mutations patterns related to antiretroviral therapy in this region. We investigated HIV resistance profile in adults failing antiretroviral regimen in Northern Brazil from January, 2004, through December, 2013. Genotype data was evaluated through Stanford University algorithm. There were 377 genotypes from different individuals to evaluate. Resistance mutations were similar to worldwide reports and related to antiretroviral exposure. Most prevalent mutations in the reverse transcriptase gene were M184V (80.1%) and K130N (40.6%). Thymidine associated mutations were more frequent in multiexperienced patients. Most common protease mutations were M46I, V82A, I54V, L90M, I84V, M46L, and L76V. Subtype B was the most prevalent (90.7%). There were differences between subtypes B and non-B mutations. We documented for the first time subtypes and patterns of HIV associated mutations in Northern Brazil. A1 subtype was identified for the first time in this area. Depending on drug regimen and how experienced the patient is, an empirical switch of a failing antiretroviral treatment could be a reasonable option.

APA, Harvard, Vancouver, ISO, and other styles

26

Renaud-Théry, Françoise, Carlos Avila-Figueroa, John Stover, Sigrid Thierry, Marco Vitoria, Vincent Habiyambere, and Yves Souteyrand. "Utilization Patterns and Projected Demand of Antiretroviral Drugs in Low- and Middle-Income Countries." AIDS Research and Treatment 2011 (2011): 1–8. http://dx.doi.org/10.1155/2011/749041.

Full text

Abstract:

Background. The rapid scale-up of antiretroviral therapy in resource-limited settings has greatly increased demand for antiretroviral medicines and raised the importance of good forward planning, especially in the context of the new 2010 WHO treatment guidelines.Methods. Forecasting of the number of people receiving antiretroviral therapy from 2010 to 2012 was produced using three approaches: linear projection, country-set targets, and a restricted scenario. Two additional scenarios were then used to project the demand for various antiretroviral medicines under a fast and slower phase-out of stavudine.Results. We projected that between 7.1 million and 8.4 million people would be receiving ART by the end of 2012. Of these, 6.6% will be on second-line therapy. High variation in forecast includes reductions in the demand for d4T and d4T increases in the demand for tenofovir, emtricitabine followed by efavirenz, ritonavir, zidovudine and lopinavir; lamivudine, atazanavir, and nevirapine.Conclusion. Despite the global economic crisis and in response to the revised treatment guidelines, our model forecasts an increasing and shifting demand for antiretrovirals in resource-limited settings not only to provide treatment to new patients, but also to those switching to less toxic regimens.

APA, Harvard, Vancouver, ISO, and other styles

27

Ghebremedhin, Beniam. "Maraviroc in Antiretroviral-Naïve HIV-1 Patients." Infectious Diseases: Research and Treatment 5 (January 2012): IDRT.S7597. http://dx.doi.org/10.4137/idrt.s7597.

Full text

Abstract:

New antiretroviral agents that are better tolerated with less side effects and novel resistance patterns are needed at all lines of human immunodeficiency virus (HIV) therapeutic strategies. The CC-chemokine receptor 5 (CCR5) antagonist maraviroc is a member of the novel class of “antiretroviral agents” that prevents the entry of HIV-1 into host cells by blocking the CCR5 coreceptor. In the MERIT (Maraviroc versus Efavirenz in Treatment-Naïve Patients) study in antiretrovial-naïve patients aged ≥16 years with CCR5-tropic HIV-1 infection, maraviroc showed noninferiority to efavirenz for virological endpoints. Evidences from trials suggest that maraviroc is effective at reducing HIV-1 viral load in antiretroviral-experienced and -naïve patients with CCR5-tropic virus, as well as in those with CCR5-tropic virus who have developed HIV-1 resistance to existing antiretroviral regimens. Recent in vitro study demonstrated that maraviroc was also active against CCR5-tropic HIV-2 strains.

APA, Harvard, Vancouver, ISO, and other styles

28

LELIÈVRE, ÉVA, and SOPHIE LE CŒUR. "Intergenerational relationships within families of HIV-infected adults under antiretroviral treatment in Northern Thailand." Ageing and Society 32, no. 4 (May 24, 2011): 561–85. http://dx.doi.org/10.1017/s0144686x11000389.

Full text

Abstract:

ABSTRACTThailand has been severely affected by AIDS/HIV. The epidemic has undermined the health of the population of working age, placing stress on intergenerational relations and threatening the social fabric. Older people in families affected by the disease, although not the main victims, have experienced major changes in relationships with their adult children and grandchildren. However, the availability of antiretrovirals has transformed HIV infection from a lethal to a chronic disease. Intergenerational relationships are analysed with data from a quantitative survey of HIV-infected adults currently receiving antiretroviral treatment in Northern Thailand. The introduction of antiretroviral treatment has eased the pressure on families. Where HIV-infected adults are more dependent on their older parents, it is because they are single and childless or single parents. While ageing parents remain a source of support for their adult children, the introduction of antiretroviral treatment has radically changed the prospects for HIV-infected adults and their regained health allows them to work, take care of their family and fulfil their filial duties as expected in Thai society. If Thailand's original aim in introducing health policies in this area was to curtail the HIV epidemic, its positive impact on intergenerational relations is an additional benefit.

APA, Harvard, Vancouver, ISO, and other styles

29

SCERPELLA, Ernesto G., and Rafael el E. D. M. CAMPO. "Avances recientes en VIH/SIDA: Terapia antiretroviral." Revista Medica Herediana 8, no. 1 (June 27, 2013): 22. http://dx.doi.org/10.20453/rmh.v8i1.533.

Full text

Abstract:

Recent advances in our understanding of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS) are leading us to explore new treatment stragegies, including the use of combination antiretroviral therapy. In this review, we present information from recently completed clinical trials explore the use of combination therapy, including ACTG 175, the Delta studies, and the NUCA studies. In addition, we present preliminary about use of protease inhibitors, the newest class of antiretrovirals.

APA, Harvard, Vancouver, ISO, and other styles

30

Celum, Connie, and Jared M. Baeten. "Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis." Antiviral Therapy 17, no. 8 (2012): 1483–93. http://dx.doi.org/10.3851/imp2492.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Tsertsvadze, Tengiz, Natalia Bolokadze, Nino Gochitashvili, Lali Sharvadze, Otar Chokoshvili, Natia Dvali, Amiran Gamkrelidze, Lali Khotenashvili, and Srdan Matic. "Experience of Antiretroviral Treatment in Georgia." Central European Journal of Public Health 17, no. 1 (March 1, 2009): 25–30. http://dx.doi.org/10.21101/cejph.a3463.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Hallal, Ronaldo, Giovanni Ravassi, Ricardo Kuchenbecker, Dirceu Greco, and Mariângela Simão. "Access to antiretroviral treatment in Brazil." Tempus Actas de Saúde Coletiva 4, no. 2 (June 24, 2010): 53. http://dx.doi.org/10.18569/tempus.v4i2.791.

Full text

Abstract:

A resposta brasileira ao HIV/AIDS foi instituída em 1986 com programas estruturados no âmbito estadual e nacional. Até à data, avanços importantes foram feitos com o desenvolvimento de uma rede estruturada para o atendimento integral às pessoas vivendo com HIV, incluindo aconselhamento e testagem em 426 unidades, 636 ambulatórios de HIV, 677 farmácias de dispensação de medicamentos de anti-retrovirais, hospitais-dia e cuidados domiciliários e uma rede de laboratório que fornece a contagem de CD4, carga viral e genotipagem do HIV. O acesso universal no Brasil está garantindo tratamento e cuidados, prolongamento da sobrevida e melhoria da qualidade de vida para cerca de 200.000 pessoas com HIV, incluindo os pacientes multi-experimentados com resistência às drogas e que estão recebendo novos medicamentos disponíveis, tais como enfuvirtida, darunavir e raltegravir. A falha terapêutica, resistência às drogas e o alto custo dos medicamentos importados representam um desafio; o contínuo para a sustentabilidade do acesso universal, sublinhando a importância de reduzir as novas infecções com uma estratégia ampla de prevenção. O desenvolvimento de estratégias de cuidados e serviços de efeitos colaterais metabólicos, doenças cardiovasculares, neoplasias, co-infecções como a tuberculose e a hepatite são outros desafios; os que a resposta nacional ao HIV no Brasil está enfocando para garantir os melhores cuidados possíveis para todos.

APA, Harvard, Vancouver, ISO, and other styles

33

Mendoza, Carmen de, Silvia Requena, Estrella Caballero, Teresa Cabezas, María Peñaranda, María José Amengual, Ana Sáez, Ana Belén Lozano, José M. Ramos, and Vincent Soriano. "Antiretroviral treatment of HIV-2 infection." Future Virology 12, no. 8 (August 2017): 461–72. http://dx.doi.org/10.2217/fvl-2017-0037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Machado-Alba, Jorge Enrique, and Xavier Vidal. "Effectiveness of antiretroviral treatment in Colombia." Revista Panamericana de Salud Pública 32, no. 5 (November 2012): 360–67. http://dx.doi.org/10.1590/s1020-49892012001100006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Wood, Robin, Linda-Gail Bekker, Des Martin, and Penny Penhall. "National antiretroviral treatment register - a necessity?" Southern African Journal of HIV Medicine 4, no. 2 (July 14, 2003): 20. http://dx.doi.org/10.4102/sajhivmed.v4i2.544.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Bassett, Mary T., and Karen Brudney. "WHO's new guidelines for antiretroviral treatment." Lancet 382, no. 9907 (November 2013): 1777–78. http://dx.doi.org/10.1016/s0140-6736(13)62538-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Fast, Patricia E., Matt A. Price, Wasima N. Rida, Anatoli Kamali, and Etienne Karita. "WHO's new guidelines for antiretroviral treatment." Lancet 382, no. 9907 (November 2013): 1778–79. http://dx.doi.org/10.1016/s0140-6736(13)62539-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Ventura-Cerdá, J. M., D. Ayago-Flores, E. Vicente-Escrig, S. Mollá-Cantavella, and M. Alós-Almiñana. "Costs and adherence to antiretroviral treatment." Farmacia Hospitalaria (English Edition) 34, no. 6 (January 2010): 284–92. http://dx.doi.org/10.1016/s2173-5085(10)70022-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Gulick, Roy M. "Antiretroviral Treatment 2010: Progress and Controversies." JAIDS Journal of Acquired Immune Deficiency Syndromes 55 (December 2010): S43—S48. http://dx.doi.org/10.1097/qai.0b013e3181f9c09e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Deeks, Steven G. "Antiretroviral treatment of HIV infected adults." BMJ 332, no. 7556 (June 22, 2006): 1489. http://dx.doi.org/10.1136/bmj.332.7556.1489.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Sewell, W. A. C. "Interrupting antiretroviral treatment needs particular care." BMJ 322, no. 7286 (March 10, 2001): 616. http://dx.doi.org/10.1136/bmj.322.7286.616.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Kagee, Ashraf, and Tracey Delport. "Barriers to Adherence to Antiretroviral Treatment." Journal of Health Psychology 15, no. 7 (August 27, 2010): 1001–11. http://dx.doi.org/10.1177/1359105310378180.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Soto Blanco, José Manuel, Isabel Ruiz Pérez, Antonio Olry De Labry Lima, José Manuel Castro Recio, Eloy Girela López, and José Joaquín Antón Basanta. "Adherence to Antiretroviral Treatment in Prisons." AIDS Research and Human Retroviruses 21, no. 8 (August 2005): 683–88. http://dx.doi.org/10.1089/aid.2005.21.683.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Sharma, Dinesh C. "India unprepared for antiretroviral treatment plan." Lancet 362, no. 9400 (December 2003): 1988. http://dx.doi.org/10.1016/s0140-6736(03)15092-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Valdiserri, Ronald O. "International Scale-Up for Antiretroviral Treatment." JAIDS Journal of Acquired Immune Deficiency Syndromes 37 (October 2004): S138—S141. http://dx.doi.org/10.1097/01.qai.0000142322.04265.64.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Draenert, R., and F. D. Goebel. "Recommendations and perspectives regarding antiretroviral treatment." DMW - Deutsche Medizinische Wochenschrift 126, no. 18 (2001): 539–43. http://dx.doi.org/10.1055/s-2001-13296.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Mayers, Douglas. "Maintenance Antiretroviral Treatment in HIV Infection." JAMA 281, no. 6 (February 10, 1999): 497. http://dx.doi.org/10.1001/jama.281.6.497.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Arribas, J. R. "Underpowered Clinical Trials of Antiretroviral Treatment." JAMA: The Journal of the American Medical Association 288, no. 17 (November 6, 2002): 2120–21. http://dx.doi.org/10.1001/jama.288.17.2120.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Thompson, Melanie A., Judith A. Aberg, Pedro Cahn, Julio S. G. Montaner, Giuliano Rizzardini, Amalio Telenti, José M. Gatell, et al. "Antiretroviral Treatment of Adult HIV Infection." JAMA 304, no. 3 (July 21, 2010): 321. http://dx.doi.org/10.1001/jama.2010.1004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Günthard, Huldrych F., Judith A. Aberg, Joseph J. Eron, Jennifer F. Hoy, Amalio Telenti, Constance A. Benson, David M. Burger, et al. "Antiretroviral Treatment of Adult HIV Infection." JAMA 312, no. 4 (July 23, 2014): 410. http://dx.doi.org/10.1001/jama.2014.8722.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Antiretroviral Treatment'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles